Emerging Evidence on Membrane Estrogen Receptors as Novel Therapeutic Targets for Central Nervous System Pathologies

• Published in: International journal of molecular sciences Vol. 24; no. 4; p. 4043
• Main Authors: Wnuk, Agnieszka, Przepiórska, Karolina, Pietrzak, Bernadeta Angelika, Kajta, Małgorzata
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 17.02.2023; MDPI
• Subjects: Adenosine; Alzheimer's disease; B cells; Brain - metabolism; Brain damage; Cell growth; Central Nervous System Diseases - drug therapy; DNA binding proteins; Endoplasmic reticulum; Estrogen; Estrogens; Gene expression; Health aspects; Kinases; Ligands; Localization; Metabolism; Molecular Targeted Therapy; Nervous system; Nervous system diseases; Neurophysiology; Nitric oxide; Phenols; Plasma; Proteins; Receptors, Estrogen - metabolism; Review; Signal Transduction; Steroids; Transcription factors; nervous system; Alzheimer’s disease; membrane estrogen receptors; rapid estrogen signaling; neuroprotection; mER; stroke
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms24044043

Nuclear- and membrane-initiated estrogen signaling cooperate to orchestrate the pleiotropic effects of estrogens. Classical estrogen receptors (ERs) act transcriptionally and govern the vast majority of hormonal effects, whereas membrane ERs (mERs) enable acute modulation of estrogenic signaling and have recently been shown to exert strong neuroprotective capacity without the negative side effects associated with nuclear ER activity. In recent years, GPER1 was the most extensively characterized mER. Despite triggering neuroprotective effects, cognitive improvements, and vascular protective effects and maintaining metabolic homeostasis, GPER1 has become the subject of controversy, particularly due to its participation in tumorigenesis. This is why interest has recently turned toward non-GPER-dependent mERs, namely, mERα and mERβ. According to available data, non-GPER-dependent mERs elicit protective effects against brain damage, synaptic plasticity impairment, memory and cognitive dysfunctions, metabolic imbalance, and vascular insufficiency. We postulate that these properties are emerging platforms for designing new therapeutics that may be used in the treatment of stroke and neurodegenerative diseases. Since mERs have the ability to interfere with noncoding RNAs and to regulate the translational status of brain tissue by affecting histones, non-GPER-dependent mERs appear to be attractive targets for modern pharmacotherapy for nervous system diseases.